| Breast Cancer Treatment Studies | Lifetime | 24 | US 13 | 99.89 |
| Gene expression and cancer classification | Lifetime | 15 | US 12 | 99.59 |
| HER2/EGFR in Cancer Research | Lifetime | 24 | US 12 | 99.82 |
| Cancer Genomics and Diagnostics | Lifetime | 68 | US 41 | 99.80 |
| Molecular Biology Techniques and Applications | Lifetime | 31 | US 20 | 99.51 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 92 | US 55 | 99.75 |
| Cancer Treatment and Pharmacology | Lifetime | 80 | US 46 | 99.71 |
| Cancer Cells and Metastasis | Lifetime | 94 | US 53 | 99.46 |
| Advanced Breast Cancer Therapies | Lifetime | 54 | US 23 | 99.49 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 975 | US 498 | 98.51 |
| Lung Cancer Treatments and Mutations | Lifetime | 762 | US 359 | 98.43 |
| Cancer-related Molecular Pathways | Lifetime | 679 | US 364 | 97.74 |
| Breast Lesions and Carcinomas | Lifetime | 336 | US 168 | 97.65 |
| PARP inhibition in cancer therapy | Lifetime | 255 | US 127 | 96.71 |
| BRCA gene mutations in cancer | Lifetime | 468 | US 249 | 96.86 |
| Bioinformatics and Genomic Networks | Lifetime | 937 | US 408 | 94.50 |
| Chemotherapy-related skin toxicity | Lifetime | 736 | US 338 | 82.64 |
| Breast Cancer Treatment Studies | 2021-2025 | 16 | US 6 | 99.76 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 92 | US 32 | 99.64 |
| Cancer Genomics and Diagnostics | 2021-2025 | 83 | US 48 | 99.30 |
| Cancer Cells and Metastasis | 2021-2025 | 34 | US 4 | 97.88 |
| Advanced Breast Cancer Therapies | 2021-2025 | 43 | US 19 | 99.18 |
| HER2/EGFR in Cancer Research | 2021-2025 | 48 | US 18 | 99.16 |
| Cancer Treatment and Pharmacology | 2021-2025 | 62 | US 23 | 98.69 |
| PARP inhibition in cancer therapy | 2021-2025 | 208 | US 79 | 93.28 |
| Breast Lesions and Carcinomas | 2021-2025 | 189 | US 63 | 91.45 |
| Cancer Risks and Factors | 2021-2025 | 442 | US 159 | 84.04 |
| BRCA gene mutations in cancer | 2021-2025 | 763 | US 328 | 84.26 |
| Estrogen and related hormone effects | 2021-2025 | 433 | US 147 | 81.18 |
| Molecular Biology Techniques and Applications | 2021-2025 | 505 | US 112 | 77.22 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 510 | US 181 | 76.20 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 882 | US 292 | 60.97 |
